Board of Directors
Kapil Dhingra, MB, BS
Director — Chairman
Kapil Dhingra, MB, BS, is managing member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies. From 1999̵;2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc., including vice president, head, Oncology Disease Biology Leadership team; and head, Oncology Clinical Development. He also worked as a senior clinical research physician at Eli Lilly. Before and during his tenures at both Eli Lilly and Hoffmann-LaRoche, Dr. Dhingra maintained an active academic career first as an assistant professor at M.D. Anderson Cancer Center, then as a clinical associate professor at Indiana University School of Medicine and, most recently, as a clinical affiliate at Memorial Sloan Kettering Cancer Center. Dr. Dhingra also serves on several emerging life science company boards. He received his MB, BS degrees (equivalent to an MD degree in the USA) from the All India Institute of Medical Sciences.
Mr. Boystak has been a director of Exosome Diagnostics since May 2009 and serves as Chairman of the Audit Committee. He is President and CEO of Brightwaters Capital, LLC, a venture capital firm based in Los Angeles that focuses on life sciences, medical devices, diagnostics, health care and nanotechnology. He also serves as Managing Director and CEO of Hudson | Brightwaters, a boutique merchant bank. Previously, Boystak spent more than 20 years as an investment banker with several major Wall Street firms and completed over $15 billion of financing and advisory transactions. He most recently served as founding Managing Director of the Global Life Science Group at Jefferies & Co. He is currently Co-Founder and Chairman of NanoPacific Holdings, Inc. and is Co-Founder and Managing Member of Bruin Biometrics, LLC. He also serves on the Health Advisory Board at The Johns Hopkins Bloomberg School of Public Health and is a member of the UCLA Foundation Board of Governors. Mr. Boystak received his B.A. from Boston University and Master of Health Science from The Johns Hopkins Bloomberg School of Public Health.
Peter Johann, PhD
Dr. Johann is a Managing General Partner of NGN Capital. He joined NGN Capital from Boehringer Ingelheim, where he was the Division Head of Corporate Development responsible for strategic planning, strategic projects, M&A, business development and licensing. Prior to this, Mr. Johann has served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim, where he was Head of Business Development and Marketing Molecular Medicine. Dr. Johann obtained his PhD from the Technical University Munich. Dr. Johann holds Board seats with Cerapedics (Observer), Exosome, Horizon Pharma (after the Nitec merger), Micromet, Resverlogix, Vivaldi Biosciences and held Board and Observer seats at Jerini and Santhera respectively.
James R. McCullough
Mr. McCullough is one of our founders and has been Chief Executive Officer since inception in May of 2008. From March of 2001 to October of 2006, Mr. McCullough was the Chief Executive Officer of AusAm Biotechnologies, Inc., a biotechnology company developing diagnostics to identify kidney and cardiovascular diseases. At AusAm, Mr. McCullough oversaw commercial development, FDA clearance, and marketing and distribution for Accumin, a diagnostic for detection of patients at risk for early-stage kidney and cardiovascular disease. He received his BA from Boston University in 1990, and his MBA from the Columbia Graduate School of Business in 1995.
Geert-Jan Mulder, MD
Geert-Jan Mulder, General Partner at Forbion Capital Partners (formerly ABN AMRO Capital Life Sciences), is an MD and accredited Pharmaceutical Physician. Before joining the pharmaceutical industry, he gained his clinical experience at the University Medical Center of Utrecht (UMC) in the field of Obstetrics and Gynecology. He then joined Searle (now Pfizer) as Medical Advisor in the field of arthritis and pain (COX-2 technology) and worked on the local and European positioning of celecoxib. After working at Searle, he joined Byk Gulden (now Nycomed) where his department was responsible for clinical development in The Netherlands dealing with the design and execution of numerous corporate clinical trials in the fields of Gastroenterology, Respiratory (asthma and COPD), Intensive Care Medicine and Imaging. Dr. Mulder currently serves on a number of boards and assists portfolio companies in their clinical development programs and overall strategy.
Mr. Slattery joined the Exosome Diagnostics Board of Directors in June 2013. He is currently the Executive Vice President and Chief Financial Officer at Baxano Surgical, Inc., after serving as a member of its Board of Directors and Chairman of its Audit Committee from November 2007 until April 2010. He also serves on the Board of Directors of CVRx, Inc. a privately held company developing implantable technology for the treatment of hypertension and heart disease, and served as a Director, Chairman of the Audit Committee and member of the Nominating & Governance Committee of Micromet, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of antibodies for the treatment of cancer, inflammation and autoimmune diseases, which was acquired by Amgen in March, 2012 for $1.2 billion. Mr. Slattery was Chief Financial Officer and Senior Vice President, Digene Corporation, a molecular diagnostics company that developed and marketed the first FDA-approved test for Human Papillomavirus that was acquired by Qiagen, N.V. in 2007 for $1.6 billion. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.
Steven L. Soignet, MD
Dr. Soignet is a co-founder of Arcus Ventures. In 2003, he became a venture partner of Cross Atlantic Partners, a healthcare and biotechnology venture capital fund. Dr. Soignet held a faculty appointment in the Developmental Chemotherapy Service at Memorial Sloan-Kettering Cancer Center, and in the Department of Medicine at Cornell University Medical Center. His primary research focus was in early phase clinical drug development in both hematological and solid tumors. He was a lead investigator of a Pilot and a large USA Multicenter Trial that led to FDA and European approval of arsenic trioxide for the treatment of relapsed acute promyelocytic leukemia. Dr. Soignet's research has been published in the New England Journal of Medicine, Leukemia, Blood, Journal of Clinical Oncology and Clinical Cancer Research. Dr. Soignet received his B.S. from the University of New Orleans, and his M.D. (AOA, honors) from Louisiana State University School of Medicine. His fellowship training was in medical oncology/hematology at Memorial Sloan-Kettering Cancer Center.